ABOUT ENZYCHEM LIFESCIENCES
Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18(Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.
PLATFORM TECHNOLOGY
EC-18 targets anti-inflammatory
pathway
Broad therapeutic platform
Developing first-in-class small molecules to target
fundamental inflammation pathways
EC-18 PIPELINE
DEVELOPMENT STAGE
CRIOM: Chemoradiation-induced Oral Mucositis
CIN: Chemotherapy-induced Neutropenia
ARS: Acute Radiation Syndrome
COVID-19: Coronavirus Disease-19
ICI: Immune Checkpoint Inhibitors (PD-1, PD-L1)
NASH: Non-alcoholic Steatohepatitis
Press Releases
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program
ENGLEWOOD CLIFFS, N.J., April 20, 2021 /PRNewswire/ — Enzychem Lifesciences (KOSDAQ: 183490), a biopharmaceutical company developing innovative medicines
Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The International Liver Congress 2021 (EASL)
ENGLEWOOD CLIFFS, N.J., April 16, 2021 /PRNewswire/ — Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innova
Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis
ENGLEWOOD CLIFFS, N.J., April 6, 2021 /PRNewswire/ — Enzychem Lifesciences (KOSDAQ: 183490), announced today that it has completed patient enrollment in Stage